Drug delivery progress in benign and malignant lesions of aging skin

Adv Drug Deliv Rev. 2020 Jan 1:153:1. doi: 10.1016/j.addr.2020.07.009.

Authors

Tarl W Prow¹, Anna Mandinova²

Affiliations

¹ Biomaterials Engineering and Nanomedicine Strand, Future Industries Institute, The University of South Australia, Mawson Lakes, SA 5001, Australia.
² Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, 149 13th Street, Charlestown, MA 02129, USA.

PMID: 32867942
DOI: 10.1016/j.addr.2020.07.009

No abstract available

Publication types

Editorial
Introductory Journal Article

MeSH terms

Antineoplastic Agents / therapeutic use
Dermatologic Agents / administration & dosage
Dermatologic Agents / therapeutic use*
Diagnostic Imaging / methods
Drug Delivery Systems / methods*
Fibroins / pharmacology
Humans
Skin Aging / drug effects
Skin Aging / physiology*
Skin Neoplasms / drug therapy*
Skin Neoplasms / pathology
Skin Physiological Phenomena

Substances

Antineoplastic Agents
Dermatologic Agents
Fibroins